Sei Investments Co. Sells 443,361 Shares of Halozyme Therapeutics, Inc. $HALO

Sei Investments Co. decreased its position in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 49.2% during the first quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 457,783 shares of the biopharmaceutical company’s stock after selling 443,361 shares during the quarter. Sei Investments Co.’s holdings in Halozyme Therapeutics were worth $29,586,000 at the end of the most recent quarter.

Several other hedge funds also recently bought and sold shares of HALO. Measured Wealth Private Client Group LLC increased its stake in Halozyme Therapeutics by 51.5% in the 4th quarter. Measured Wealth Private Client Group LLC now owns 365 shares of the biopharmaceutical company’s stock worth $25,000 after buying an additional 124 shares in the last quarter. Abel Hall LLC raised its holdings in Halozyme Therapeutics by 4.2% during the fourth quarter. Abel Hall LLC now owns 3,216 shares of the biopharmaceutical company’s stock valued at $216,000 after acquiring an additional 129 shares during the period. StoneX Group Inc. lifted its position in shares of Halozyme Therapeutics by 3.8% in the fourth quarter. StoneX Group Inc. now owns 3,650 shares of the biopharmaceutical company’s stock valued at $246,000 after acquiring an additional 132 shares in the last quarter. Moran Wealth Management LLC lifted its position in shares of Halozyme Therapeutics by 0.4% in the fourth quarter. Moran Wealth Management LLC now owns 35,596 shares of the biopharmaceutical company’s stock valued at $2,396,000 after acquiring an additional 151 shares in the last quarter. Finally, Twin Capital Management Inc. boosted its stake in shares of Halozyme Therapeutics by 1.4% in the first quarter. Twin Capital Management Inc. now owns 11,422 shares of the biopharmaceutical company’s stock worth $738,000 after acquiring an additional 161 shares during the period. Institutional investors own 97.79% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts recently issued reports on the company. HC Wainwright reiterated a “buy” rating and set a $95.00 target price on shares of Halozyme Therapeutics in a research report on Tuesday, July 21st. Benchmark reissued a “buy” rating on shares of Halozyme Therapeutics in a report on Tuesday, July 21st. Weiss Ratings upgraded Halozyme Therapeutics from a “hold (c)” rating to a “buy (b-)” rating in a research note on Tuesday, May 12th. Wall Street Zen raised shares of Halozyme Therapeutics from a “hold” rating to a “buy” rating in a report on Saturday, May 16th. Finally, Morgan Stanley reduced their price objective on shares of Halozyme Therapeutics from $96.00 to $93.00 and set an “overweight” rating on the stock in a research report on Tuesday, May 12th. Eight analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $81.60.

Insiders Place Their Bets

In other news, CEO Helen Torley sold 20,000 shares of the business’s stock in a transaction dated Tuesday, May 12th. The shares were sold at an average price of $71.75, for a total value of $1,435,000.00. Following the sale, the chief executive officer directly owned 767,780 shares in the company, valued at $55,088,215. The trade was a 2.54% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Bernadette Connaughton sold 1,625 shares of the company’s stock in a transaction dated Wednesday, July 1st. The shares were sold at an average price of $76.71, for a total transaction of $124,653.75. Following the sale, the director owned 42,044 shares in the company, valued at $3,225,195.24. This represents a 3.72% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 74,102 shares of company stock valued at $5,205,798 in the last three months. Corporate insiders own 2.50% of the company’s stock.

Halozyme Therapeutics Stock Down 0.5%

NASDAQ HALO opened at $81.48 on Tuesday. The stock has a 50 day moving average price of $73.36 and a 200-day moving average price of $70.63. Halozyme Therapeutics, Inc. has a one year low of $57.67 and a one year high of $83.50. The company has a debt-to-equity ratio of 8.81, a quick ratio of 2.33 and a current ratio of 2.76. The company has a market capitalization of $9.66 billion, a P/E ratio of 29.31, a P/E/G ratio of 0.34 and a beta of 0.84.

Halozyme Therapeutics (NASDAQ:HALO) last announced its quarterly earnings results on Monday, May 11th. The biopharmaceutical company reported $1.60 earnings per share for the quarter, topping the consensus estimate of $1.54 by $0.06. The company had revenue of $376.71 million for the quarter, compared to analysts’ expectations of $358.60 million. Halozyme Therapeutics had a net margin of 23.13% and a return on equity of 187.91%. Halozyme Therapeutics’s quarterly revenue was up 42.2% on a year-over-year basis. During the same quarter in the previous year, the business posted $1.11 earnings per share. Halozyme Therapeutics has set its FY 2026 guidance at 7.750-8.250 EPS. As a group, equities analysts predict that Halozyme Therapeutics, Inc. will post 7.54 EPS for the current fiscal year.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company’s flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.